Skip to content

Carbon monoxide-releasing mesoporous polydopamine nanoplatform for lysosomal disruption and synergistic tumor therapy.

Nov 2026 · International journal of pharmaceutics · pp. 127670 · 0 citations · 32 references
Medicine

Abstract

Lysosomes, pivotal in tumor progression and therapy resistance, sustain cancer survival through drug tolerance and stress adaptation. Conventional lysosome-disrupting approaches faced transient efficacy from poor targeting or cellular repair mechanisms. To address this, we engineered a biomimetic nanoplatform (FeCO@MP-P) integrating polydopamine's pH/photothermal responsiveness with gas-generating FeCO and charge-reversal PEOz coating. The charge-reversal strategy enhanced cellular uptake by 1.8-fold. Subsequently, the combined application of multiple lysosome-disrupting strategies achieved efficient lysosomal damage. Following cellular internalization, FeCO@MP-P initially accumulated in lysosomes, where H2O2-responsive CO release, Fe-mediated ROS generation, and NIR-induced photothermal stress collectively contributed to lysosomal damage. Subsequent cytoplasmic redistribution further amplified intracellular oxidative stress, mitochondrial dysfunction, and apoptosis. Ultimately, FeCO@MP-P suppressed approximately 95% of tumor growth. This study pioneers a lysosome-targeted strategy that couples irreversible organelle disruption with ROS potentiation, demonstrating a paradigm to subvert adaptive tumor defenses through mechanistically synchronized nanomaterials.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.